Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202445121> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W3202445121 endingPage "88" @default.
- W3202445121 startingPage "84" @default.
- W3202445121 abstract "Aggressive systemic mastocytosis (ASM) is a very rare subtype of systemic mastocytosis (SM) and, together with systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL), it belongs to advanced systemic mastocytosis (AdvSM). Different strategies of systemic treatment are used in patients with AdvSM. The protocols base on the cladribine, interferon, allogeneic hematopoietic stem cell transplantation, polychemotherapy or the midostaurin — the only approved drug therapy in AdvSM. Options available in Poland — cladribine and interferon — are characterized by a non-lasting effect and, unfortunately, midostaurin still remains unreimbursed for patients. On October 5, 2018, The Polish Agency for Health Technology Assessment and Tariff System approved the midostaurin to be financed within The Emergency Access to Drug Technologies Programme in ASM with the c-KIT D816V mutation. Based on a case report, the following manuscript describes authors’ experiences with the use of midostaurin. The aim of the article is to present an overview of the current status of midostaurin in the treatment of ASM and to summarize the results of clinical trials, focusing on its effectiveness and safety. Authors, hereby, report a case of a patient diagnosed in 2000 with cutaneous mastocytosis (CM), that developed a transformation to ASM in 2015. The following lines of treatment were used: cladribine, pegylated interferon alpha, dasatinib. Significant side effects were observed after each line, without obtaining a lasting response to treatment. In July 2020, patient began a therapy with midostaurin. Afterwards, a normalization of peripheral blood count parameters together with reduction of serum tryptase level were observed, without noticing any adverse effects ." @default.
- W3202445121 created "2021-10-11" @default.
- W3202445121 creator A5021865256 @default.
- W3202445121 creator A5033857845 @default.
- W3202445121 date "2021-11-30" @default.
- W3202445121 modified "2023-10-16" @default.
- W3202445121 title "The use of midostaurin in aggressive systemic mastocytosis (ASM) with the c-KIT D816V mutation within The Emergency Access to Drug Technologies Programme" @default.
- W3202445121 doi "https://doi.org/10.5603/hcp.2021.0011" @default.
- W3202445121 hasPublicationYear "2021" @default.
- W3202445121 type Work @default.
- W3202445121 sameAs 3202445121 @default.
- W3202445121 citedByCount "0" @default.
- W3202445121 crossrefType "journal-article" @default.
- W3202445121 hasAuthorship W3202445121A5021865256 @default.
- W3202445121 hasAuthorship W3202445121A5033857845 @default.
- W3202445121 hasBestOaLocation W32024451211 @default.
- W3202445121 hasConcept C126322002 @default.
- W3202445121 hasConcept C143998085 @default.
- W3202445121 hasConcept C203014093 @default.
- W3202445121 hasConcept C2776178377 @default.
- W3202445121 hasConcept C2776481607 @default.
- W3202445121 hasConcept C2777583451 @default.
- W3202445121 hasConcept C2778461978 @default.
- W3202445121 hasConcept C2778729363 @default.
- W3202445121 hasConcept C2779200787 @default.
- W3202445121 hasConcept C2779536868 @default.
- W3202445121 hasConcept C2780007613 @default.
- W3202445121 hasConcept C2780581156 @default.
- W3202445121 hasConcept C2909179924 @default.
- W3202445121 hasConcept C71924100 @default.
- W3202445121 hasConceptScore W3202445121C126322002 @default.
- W3202445121 hasConceptScore W3202445121C143998085 @default.
- W3202445121 hasConceptScore W3202445121C203014093 @default.
- W3202445121 hasConceptScore W3202445121C2776178377 @default.
- W3202445121 hasConceptScore W3202445121C2776481607 @default.
- W3202445121 hasConceptScore W3202445121C2777583451 @default.
- W3202445121 hasConceptScore W3202445121C2778461978 @default.
- W3202445121 hasConceptScore W3202445121C2778729363 @default.
- W3202445121 hasConceptScore W3202445121C2779200787 @default.
- W3202445121 hasConceptScore W3202445121C2779536868 @default.
- W3202445121 hasConceptScore W3202445121C2780007613 @default.
- W3202445121 hasConceptScore W3202445121C2780581156 @default.
- W3202445121 hasConceptScore W3202445121C2909179924 @default.
- W3202445121 hasConceptScore W3202445121C71924100 @default.
- W3202445121 hasIssue "2" @default.
- W3202445121 hasLocation W32024451211 @default.
- W3202445121 hasOpenAccess W3202445121 @default.
- W3202445121 hasPrimaryLocation W32024451211 @default.
- W3202445121 hasRelatedWork W11313001 @default.
- W3202445121 hasRelatedWork W13021636 @default.
- W3202445121 hasRelatedWork W14019567 @default.
- W3202445121 hasRelatedWork W16114088 @default.
- W3202445121 hasRelatedWork W18760892 @default.
- W3202445121 hasRelatedWork W19038098 @default.
- W3202445121 hasRelatedWork W2445216 @default.
- W3202445121 hasRelatedWork W5199437 @default.
- W3202445121 hasRelatedWork W6817147 @default.
- W3202445121 hasRelatedWork W7456156 @default.
- W3202445121 hasVolume "12" @default.
- W3202445121 isParatext "false" @default.
- W3202445121 isRetracted "false" @default.
- W3202445121 magId "3202445121" @default.
- W3202445121 workType "article" @default.